Panion & Bf BiotechTPE:1760 -2.30%74 EBITDA Margin % is 20.42% as of Dec. 2025, which is 9% above its 10-year median of 18.73. GuruFocus rates TPE:1760 with a GF Score™ of 74/100 and a GF Value™ of NT$95.99 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Panion & Bf Biotech ranks better than 84.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Panion & Bf Biotech's EBITDA for the
three
months ended in Dec. 2025 was NT$112 Mil. Panion & Bf Biotech's Revenue for the
three
months ended in Dec. 2025 was NT$546 Mil. Therefore, Panion & Bf Biotech's EBITDA margin for the quarter that ended in Dec. 2025 was 20.42%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Panion & Bf Biotech EBITDA Margin % Related Terms
Panion & Bf Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Panion & Bf Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1760 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Panion & Bf Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panion & Bf Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panion & Bf Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Panion & Bf Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech (TPE:1760) has a EBITDA Margin % of 20.42% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Panion & Bf Biotech and its competitors. This is near median its historical median of 18.73. Over the past decade, Panion & Bf Biotech's EBITDA Margin % has ranged from 11.35 to 21.65. According to the industry distribution chart, Panion & Bf Biotech ranks #149 out of 944 companies in the Biotechnology industry, placing it in the top 15.8%.
Is Panion & Bf Biotech's EBITDA Margin % too high?
Panion & Bf Biotech's current EBITDA Margin % of 20.42% is near median its 10-year median of 18.73. Over the past 10 years, this metric has ranged from a low of 11.35 to a high of 21.65. Based on the distribution chart, Panion & Bf Biotech ranks #149 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Panion & Bf Biotech has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panion & Bf Biotech ranks #149 out of 944 companies for EBITDA Margin %. This places Panion & Bf Biotech in the top 16% of its industry — outperforming the majority of peers. Historically, Panion & Bf Biotech's own EBITDA Margin % has ranged from 11.35 to 21.65 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Panion & Bf Biotech and its competitors. Panion & Bf Biotech's current EBITDA Margin % is 20.42%, which is near median its own 10-year median of 18.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$95.99, compared to a current price of NT$59.60 — trading 37.9% below its estimated fair value. The current EBITDA Margin % is 20.42%, which is near median its 10-year median of 18.73. Panion & Bf Biotech's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current EBITDA Margin % is 20.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?
Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued.
The current stock price of NT$59.60 is trading 37.9% below its estimated GF Value™ of NT$95.99.
GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1760:
EBITDA Margin %: 20.42% (near median its 10-year median of 18.73)
GF Value™: NT$95.99 vs. price of NT$59.60 (37.9% below fair value)
No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
74GF Score
Get the complete analysis for TPE:1760
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1760 has been successfully added to your 
